Bridges Investment Management Decreased Biogen Com (BIIB) Position By $303,610; The Bank of Nova Scotia (TSE:BNS) Covered By 7 Bulls

Among 8 analysts covering Bank of Nova Scotia (TSE:BNS), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Bank of Nova Scotia had 54 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of The Bank of Nova Scotia (TSE:BNS) earned “Outperform” rating by Scotia Capital on Friday, February 3. The stock of The Bank of Nova Scotia (TSE:BNS) earned “Outperform” rating by RBC Capital Markets on Wednesday, June 1. The firm has “Market Perform” rating by KBW given on Tuesday, August 18. Scotia Capital maintained the stock with “Outperform” rating in Wednesday, March 1 report. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, December 2. The rating was downgraded by TD Securities on Wednesday, March 1 to “Buy”. The firm earned “Overweight” rating on Tuesday, May 23 by Barclays Capital. The rating was initiated by Bank of America on Tuesday, November 1 with “Buy”. BMO Capital Markets maintained The Bank of Nova Scotia (TSE:BNS) rating on Wednesday, December 6. BMO Capital Markets has “Outperform” rating and $86 target. The firm earned “Outperform” rating on Wednesday, August 31 by RBC Capital Markets. See The Bank of Nova Scotia (TSE:BNS) latest ratings:

06/12/2017 Broker: BMO Capital Markets Rating: Outperform New Target: $86.00 Maintain
17/11/2017 Broker: Citigroup Rating: Old Target: $90.00 New Target: $93.00 Target Up
01/11/2017 Broker: Canaccord Genuity Rating: Old Target: $88.00 New Target: $92.00 Target Up

Bridges Investment Management Inc decreased Biogen Inc Com (BIIB) stake by 7.88% reported in 2017Q3 SEC filing. Bridges Investment Management Inc sold 970 shares as Biogen Inc Com (BIIB)’s stock declined 13.45%. The Bridges Investment Management Inc holds 11,340 shares with $3.55M value, down from 12,310 last quarter. Biogen Inc Com now has $73.28B valuation. The stock decreased 0.07% or $0.25 during the last trading session, reaching $346.5. About 1.51M shares traded or 31.80% up from the average. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since January 25, 2017 and is uptrending. It has underperformed by 11.76% the S&P500.

Among 32 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 23 have Buy rating, 0 Sell and 9 Hold. Therefore 72% are positive. Biogen Idec Inc. has $450 highest and $268 lowest target. $354.60’s average target is 2.34% above currents $346.5 stock price. Biogen Idec Inc. had 99 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co with “Buy” on Tuesday, October 24. Wells Fargo maintained the shares of BIIB in report on Friday, December 4 with “Outperform” rating. The stock has “Buy” rating by Cowen & Co on Tuesday, August 25. Robert W. Baird maintained the shares of BIIB in report on Friday, August 25 with “Hold” rating. Atlantic Securities initiated the shares of BIIB in report on Friday, December 18 with “Overweight” rating. Stifel Nicolaus maintained it with “Hold” rating and $30000 target in Tuesday, July 25 report. Jefferies maintained Biogen Inc. (NASDAQ:BIIB) rating on Wednesday, October 5. Jefferies has “Hold” rating and $316 target. The rating was downgraded by Raymond James to “Market Perform” on Thursday, September 21. Nomura maintained it with “Buy” rating and $35500 target in Friday, July 14 report. The rating was initiated by Citigroup on Thursday, February 25 with “Buy”.

Investors sentiment increased to 1.13 in Q3 2017. Its up 0.25, from 0.88 in 2017Q2. It is positive, as 59 investors sold BIIB shares while 283 reduced holdings. 96 funds opened positions while 292 raised stakes. 181.16 million shares or 0.28% more from 180.66 million shares in 2017Q2 were reported. Adirondack Trust Company accumulated 63 shares. Eaton Vance Mngmt owns 448,373 shares or 0.36% of their US portfolio. The Massachusetts-based Amundi Pioneer Asset has invested 0.05% in Biogen Inc. (NASDAQ:BIIB). Fifth Third Comml Bank has 0.17% invested in Biogen Inc. (NASDAQ:BIIB) for 75,658 shares. Outfitter Ltd owns 24,206 shares for 2.67% of their portfolio. 92,158 are held by Commerzbank Aktiengesellschaft Fi. Department Mb National Bank & Trust N A has 1.23% invested in Biogen Inc. (NASDAQ:BIIB) for 36,549 shares. Ontario – Canada-based Canada Pension Plan Inv Board has invested 0.23% in Biogen Inc. (NASDAQ:BIIB). Optimum Inv Advsr stated it has 1,089 shares or 0.11% of all its holdings. Boston Private Wealth Ltd Liability Co owns 1,435 shares or 0.02% of their US portfolio. Dynamic Mngmt Limited, a United Kingdom-based fund reported 5,218 shares. Glob Endowment Mgmt Lp has invested 0.04% in Biogen Inc. (NASDAQ:BIIB). Signaturefd Lc invested in 1,309 shares. Lazard Asset Mngmt Ltd reported 747,070 shares. Gulf Interest State Bank (Uk) Limited invested 0.29% in Biogen Inc. (NASDAQ:BIIB).

Since January 9, 2018, it had 0 buys, and 1 sale for $1.92 million activity. PANGIA ROBERT W sold $1.92 million worth of stock.

The stock decreased 0.29% or $0.24 during the last trading session, reaching $81.82. About 2.29 million shares traded or 35.99% up from the average. The Bank of Nova Scotia (TSE:BNS) has 0.00% since January 25, 2017 and is . It has underperformed by 16.70% the S&P500.

The Bank of Nova Scotia provides various financial services in North America, Latin America, the Caribbean and Central America, and the Asia-Pacific. The company has market cap of $98.15 billion. It offers financial advice, solutions, and day-to-day banking products, including debit cards, checking and saving accounts, credit cards, investments, mortgages, loans, and related creditor insurance products to individuals and small businesses; and commercial banking solutions comprising lending, deposit, cash management, and trade finance solutions to medium and large businesses comprising automotive dealers and their customers. It has a 12.61 P/E ratio. The firm also provides a suite of investment and wealth management advice, services, products, and solutions to customers, as well as advisors.